SWOG S2206

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

For more information about this clinical trial, click here

Schema & Eligibility SWOG S2206

Available at:

CoxHealth Medical Center, Springfield, MO
Mercy Hospital, Springfield, MO
Delbert Day Cancer Institute at PCRMC, Rolla, MO
Freeman Health System, Joplin, MO
Good Samaritan Regional Health Center, Mt. Vernon, IL
Saint Mary’s Hospital, Centralia, IL
OSF Saint Anthony Health Center, Alton, IL
Mercy Hospital, St. Louis, MO
Mercy South, St. Louis, MO
Mercy Hospital, Oklahoma City, OK
Mercy Hospital, Fort Smith, AK
Mercy Hospital, Joplin, MO
Mercy Clinic Cancer & Hematology, Rolla, MO
Mosaic Life Care, St. Joseph, MO
Central Care Cancer Center, Bolivar, MO
Central Care Cancer Center, Great Bend, KS
Central Care Cancer Center, Garden City, KS
Lake Regional Hospital, Osage Beach, MO

Ask your physician about participating in this clinical trial or call us.